# In an op-ed, Professor Aswath Damodaran cautions against Pfizer's acquisition of Allergan

1 Faculty News November 24, 2015 ![Forbes logo](/sites/default/files/styles/246w/public/assets/images/con_030508.jpg?itok=SId6k3bx)>

Excerpt from [Forbes](http://www.forbes.com/sites/aswathdamodaran/2015/11/24/pfizer-allergan-why-growth-at-any-price-is-a-dangerous-game/) -- "The bottom line is that this looks like a bad deal for the wrong company, at the wrong time and at the wrong price -- the wrong company because Allergan’s accounting statements are a mine field due to acquisition accounting, the wrong time because we may actually be on the verge of a major change in US corporate tax code and at the wrong price because of the premium on an already large market capitalization."

[Read more](http://www.forbes.com/sites/aswathdamodaran/2015/11/24/pfizer-allergan-why-growth-at-any-price-is-a-dangerous-game/)